Ambrilia Biopharma Inc. Completes Korean Licensing Partnership with Shin Poong Pharmaceutical Co., Ltd. for its Long-Acting Formulation of Octreotide

Published: Jul 17, 2007

MONTREAL, QUEBEC--(MARKET WIRE)--Jul 17, 2007 -- Ambrilia Biopharma Inc. (Toronto:AMB.TO - News), a biopharmaceutical company developing novel small molecules and peptides to treat infectious diseases and cancer, announced today the signing of a licensing and distribution agreement with Shin Poong Pharmaceutical Co. of Seoul, Korea, for its sustained-release formulation of Octreotide for the treatment of acromegaly. As previously announced, Ambrilia's Octreotide is currently in Phase III clinical trials.

Back to news